INNOCARE PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.06 HKD | -5.80% |
|
-18.80% | -41.07% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
InnoCare Pharma Ltd is a China-based company mainly engaged in the research, development, manufacture, and commercialization of biological medicines. The Company is focused on tumor, autoimmune diseases, and other fields with unsatisfied clinical needs, and its product pipeline includes ICP-022, ICP-B04, ICP-490, ICP-192, ICP-723, ICP-022, among others. The Company mainly conducts business mainly in China and the United States.
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.984
CNY
Average target price
8.987
CNY
Spread / Average Target
+125.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -41.07% | 1.11B | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.43% | 21.66B | |
| -18.35% | 20.77B | |
| -8.03% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- 9969 Stock
- News InnoCare Pharma Limited
- InnoCare Pharma Narrows Loss on License-Out Payment From Biogen for Multiple Sclerosis Drug
